Medical Meetings

Learn about the latest myeloma research. Get a front row seat at the most critical medical meetings. Watch Dr. Brian Durie, IMF Chairman, address issues that are important to the entire myeloma community. IMF TV brings it all to you.

Jun
05
CALGB/ECOG 100104 (Alliance) study: Lenalidomide vs placebo maintenance after stem cell transplant
Philip McCarthy, MD Roswell Park Cancer Institute Buffalo, NY, USA Background: At a prespecified interim analysis (Dec 2009), the phase 3 CALGB study results surpassed the prespecified superiority(...)
Jun
04
ASCO 2017: What's New and Promising in Multiple Myeloma Research
Dr. Philip McCarthy from the Roswell Park Cancer Institute, talks about the multiple myeloma clinical trials and abstracts presented at the annual American Society of Clinical Oncologists (ASCO)(...)
Jun
04
Phase 3 ELOQUENT-2 study: Elotuzumab plus lenalidomide/dexamethasone vs Ld in relapsed/refractory multiple myeloma (RRMM)
Background: Elotuzumab, an immunostimulatory monoclonal antibody, has a dual mechanism of action: directly activating NK cells and tagging myeloma cells for recognition/death via antibody-dependent(...)
Jun
04
ASCO 2017: Multiple Myeloma Highlights -- Dr. Joseph Mikhael
Dr. Joseph Mikhael from the Mayo Clinic, talks about the multiple myeloma clinical trials and abstracts presented at the annual American Society of Clinical Oncologists (ASCO) meeting in Chicago, IL.
Jun
03
CheckMate 602: A phase 3 trial of combinations of nivo, elo, pom and dex in RRMM
Background: Multiple myeloma (MM) cells may evade immune surveillance by suppressing immune responses through the PD-1 pathway, via upregulation of PD-L1.1Nivolumab (nivo), a PD-1 immune checkpoint(...)
Jun
03
A phase 1/2 study of durvalumab in combination with len with or without dex in patients with newly diagnosed multiple myeloma
Background: LEN + DEX (Rd) is approved for pts with newly diagnosed MM, including those who are transplant non-eligible (TNE). DURVA is a monoclonal antibody to programmed death ligand 1 (PD-L1) that(...)